Mergers & Acquisitions ·
On August 1, 2026, Indivior Pharmaceuticals, Inc. entered into an Agreement and Plan of Merger with Supernus…
INDVSupernus, Inc.
On August 1, 2026, Indivior Pharmaceuticals, Inc. entered into an Agreement and Plan of Merger with Supernus Pharmaceuticals, Inc., under which a wholly owned subsidiary of Indivior will merge with and into Supernus. Supernus will survive as a wholly owned subsidiary of Indivior, which will be renamed Supernus, Inc. Each share of Supernus common stock will convert into 1.5401 shares of Indivior common stock. Following the merger, Indivior stockholders are expected to own approximately 56.5% of the combined company on a fully diluted basis, while Supernus stockholders will own approximately 43.5%. Jack A. Khattar will serve as CEO and Timothy C. Dec as CFO of the combined entity. To fund a special cash dividend of $1 billion payable to Indivior shareholders prior to closing, Citibank has committed to provide a $650 million senior secured term loan facility. The transaction is subject to customary conditions, including stockholder approvals and antitrust clearance, with termination fees of $174.0 million for Indivior and $101.0 million for Supernus under specific circumstances. Indivior Pharmaceuticals operates in the pharmaceutical industry, specializing in addiction treatment therapies.